Siluria Technologies, Inc.: Series B $20M

Posted in I - Series B, Q - 3Q11, R - WEST, X - Biofuel, XX - CA

Siluria Technologies (San Francisco, CA) a development-stage biofuels company focused on methane conversion, closed a $20M Series B financing. Participants include Wellcome Trust, Alloy Ventures, Arch Venture Partners, Kleiner Perkins, Altitude Life Science Ventures, Lux Capital and Presidio Ventures.

Jul

2010

Castlight Health, Inc.: Series C $60M

Posted in I - Series C, Q - 2Q10, R - WEST, X - TeleMedicine, XX - CA

Castlight Health (San Francisco) a development-stage consumer facing personalized healthcare platform, closed a $60M Series C financing. Participants include Morgan Stanley Investment Management, Wellcome Trust, US Venture Partners, Cleveland Clinic, Maverick Capital, Oak Investment Partners and Venrock.

Apr

2010

Achaogen, Inc. : Series C $56M

Posted in I - Series C, Q - 2Q10, R - WEST, X - Antibacterial, X - MDR, XX - CA

Achaogen (San Francisco, CA) a clinical-stage a biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat life-threatening, multi-drug resistant bacterial infections, closed a $56M Series C financing. Participants include Frazier Healthcare Ventures, Alta Partners, 5 AM Ventures, ARCH Venture Partners, Domain Associates, Venrock Associates, Versant Ventures and Wellcome Trust.

Jan

2010

Oxagen, Ltd.: Series C $25.9M

Posted in I - Series C, Q - 4Q09, R - INTERNATIONAL, X - Asthma, X - Inflammation, X - Respiratory, X - Rhinitis

Oxagen (United Kingdom) a clinical-stage biopharmaceutical company focused on asthma and allergic rhinitis based drug company focused on inflammation, closed a $25.M Series C financing. Participants include MPM Capital, SV Life Sciences, Advent Ventures, Bessemer Venture Partners, Omega Ventures, Abingworth, International Bio Trust, Red Abbey Venture Partners and Wellcome Trust.

Note: 2009 Year-in-Review Trend Analysis Coming [...]

Jan

2010

Integrated Diagnostics, Inc.: Series A $30M

Posted in I - Series A, Q - 4Q09, R - NORTH WEST, X - Device (Diagnostic), XX - WA

Integrated Diagnostics (Seattle, WA) a development-stage diagnostics company focused on rapid biomarker validation and parallel organ-centric assays, closed a $30M Series A financing. Participants include Interwest Partners, The Wellcome Trust and Dievini Hopp Biotech Holding.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Jan

2010

Nabriva Therapeutics, AG: Series B $22M

Posted in I - Series B, Q - 4Q09, R - INTERNATIONAL, X - Antiinfective, X - MRSA

Nabriva Therapeutics (Austria) a clinical-stage based developer of antibiotics for treating multi-drug resistant pathogens, closed a $22M Series B financing. Participants include Nomura Phase 4 Ventures, HBM Partners, Wellcome Trust, GLS Ventures and Novartis Venture Fund.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

to top of page...